Actemra® (tocilizumab) – New orphan indication
August 30, 2017 – The FDA approved Genentech’s Actemra (tocilizumab) injection, for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older.
Top